1.
United European Gastroenterol J
; 8(3): 353-354, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32213039
2.
United European Gastroenterol J
; 7(10): 1408-1410, 2019 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31839966
3.
Mycoses
; 59(2): 101-7, 2016 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26648179
RESUMO
A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.